Trial Profile
A Phase 2A Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged ≥6 to <18 Years With Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Regeneron Pharmaceuticals
- 08 Nov 2020 Results from 52 week open label extension (OLE) study of children 6-12 years old with severe AD, published in the British Journal of Dermatology
- 24 Sep 2020 Results from an open-label phase IIa study and subsequent phase III open-label extension study published in the British Journal of Dermatology
- 08 Oct 2019 Results from a phase IIa open label trial and subsequent phase III open label extension study published in the British Journal of Dermatology